

Supplementary data

Supplementary table 1. Baseline characteristics of study participants

Variables	
N	115
Age, years	56.3 ± 11.1
Gender, male/female	71/44
Duration of diabetes, years	16.1 ± 8.0
Hypertension, n (%)	102 (88.7)
Established cardiovascular disease, n (%)	32 (27.8)
- Coronary heart disease, n (%)	24 (20.9)
- Stroke, n (%)	6 (5.2)
- Peripheral vascular disease, n (%)	4 (3.5)
Congestive heart failure, n (%)	5 (4.3)
Cancer, n (%)	6 (5.2)
Estimated glomerular filtration rate (ml/min/1.73m ²)	90.5 ± 20.5
Background anti-diabetic agents	
- Metformin, n (%)	110 (95.7)
- Dipeptidyl peptidase 4 inhibitors, n (%)	44 (38.3)
- Sulphonylurea, n (%)	44 (38.3)
- Glitazones, n (%)	6 (5.2)
- Glucagon like peptide receptor agonist, n (%)	7 (6.1)
- Insulin, n (%)	66 (57.4)
Lipid-lowering treatment, n (%)	76 (66.1)
Angiotensin converting enzymes inhibitors / angiotensin receptor blockers, n (%)	84 (73.0)
Diuretics, n (%)	14 (12.2)